Condition: Large Cell Neuroendocrine Carcinoma of the Lung · Sponsor: Centre Leon Berard
The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review
This description comes directly from the study's public registry record.
Julien GAUTIER · +33 4 26 55 68 29 · julien.gautier@lyon.unicancer.fr
Luc ODIER, MD · lodier@hno.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Intercommunal Aix-Pertuis | Aix-en-Provence, France | Active Not Recruiting |
| Chu Amiens Picardie Site Sud | Amiens, France | Not Yet Recruiting |
| Chu Angers | Angers, France | Not Yet Recruiting |
| CENTRE HOSPITALIER d'AVIGNON | Avignon, France | Not Yet Recruiting |
| CHU BREST Cavale Blanche | Brest, France | Not Yet Recruiting |
| Centre Francois Baclesse | Caen, France | Not Yet Recruiting |
| Chu Gabriel Montpied | Clermont-Ferrand, France | Not Yet Recruiting |
| Centre Hospitalier Intercommunal de Creteil | Créteil, France | Not Yet Recruiting |
| Chu Annecy Genevois | Épagny, France | Active Not Recruiting |
| Chu Grenoble Alpes | Grenoble, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Not Yet Recruiting |
| Chu Dupuytren | Limoges, France | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06393816